Globus Medical Inc (GMED) Stock Price & Analysis
Globus Medical Inc (GMED) rose 5.39% to USD 82.52 as of June 10, 2026 at 01:56 UTC, according to Nexqual real-time market data.
GMED last closed at USD 78.3; the session ranged USD 78.73–82.97 on volume of 1,482,498 shares. Market capitalization is $11.20B, with a 52-week range of USD 51.79–101.4 (NYQ). Source: Nexqual, June 10, 2026 at 01:56 UTC.
Key Statistics (as of June 10, 2026 at 01:56 UTC)
| Price | USD 82.52 |
|---|---|
| Change | ▲ 5.39% (up) |
| Previous Close | USD 78.3 |
| Open | USD 79.12 |
| Day Range | USD 78.73 – 82.97 |
| 52-Week Range | USD 51.79 – 101.4 |
| Volume | 1,482,498 shares |
| Market Cap | $11.20B |
| Exchange | NYQ |
Technical Analysis (GMED)
Nexqual's technical model rates GMED "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 01:56 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.9 (neutral) |
| vs SMA50 | Below (USD 86.26) |
| MACD | -1.6 (negative) |
Analyst Ratings (GMED)
Wall Street analysts rate GMED "Buy" based on 11 analysts, with a mean price target of USD 110 (range USD 87–122), per Nexqual as of June 10, 2026 at 01:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 110 |
| High Target | USD 122 |
| Low Target | USD 87 |
| Buy / Hold / Sell | 9 / 4 / 0 |
Earnings (GMED)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.1 |
| Revenue Estimate | $783.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.12 vs est 0.92 ▲ beat |
| 2025-12-31 | USD 1.28 vs est 1.15 ▲ beat |
| 2025-09-30 | USD 1.18 vs est 0.78 ▲ beat |
| 2025-06-30 | USD 0.86 vs est 0.75 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:56 UTC.
Financials & Fundamentals (GMED)
| Total Revenue | $3.10B |
|---|---|
| Revenue Growth (YoY) | +27.00% |
| Gross Margin | +68.49% |
| Operating Margin | +21.32% |
| Profit Margin | +18.92% |
| ROE | +13.30% |
| Debt / Equity | 2.45 |
| Current Ratio | 4.56 |
| Total Cash | $629.85M |
| Total Debt | $115.94M |
| Free Cash Flow | $341.06M |
Source: Nexqual, June 10, 2026 at 01:56 UTC.
Financial Health Score (GMED)
Nexqual rates Globus Medical Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:56 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 21% |
| Balance Sheet | Strong — $630M cash vs $116M debt, net cash position |
| Cash Flow | Solid — FCF $341M, 12% margin |
| Efficiency | Mixed — ROE 13%, ROA 8.2% |
Ownership (GMED)
| Insider Ownership | +0.71% |
|---|---|
| Institutional Ownership | +101.57% |
| Shares Outstanding | 113.31M |
| Float | 111.72M |
| Short % of Float | +3.48% |
Source: Nexqual, June 10, 2026 at 01:56 UTC.
Leadership (GMED)
Globus Medical Inc is led by Keith W. Pfeil (age 46), CEO, President & Director, per Nexqual as of June 10, 2026 at 01:56 UTC.
| CEO, President & Director | Keith W. Pfeil (age 46) |
|---|---|
| Co-Founder & Executive Chairman | David C. Paul (age 58) |
| Senior VP & CFO | Kyle R. Klin (age 39) |
| Senior Vice President of Business Development & Investor Relations | Brian J. Kearns (age 58) |
Major Backers & Investors (GMED)
Notable institutional backers of Globus Medical Inc include Janus Henderson Group PLC, Invesco, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, according to Nexqual as of June 10, 2026 at 01:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 5.62% |
| Invesco | 3.18% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 2.44% |
| Sculptor Capital LP | 2.25% |
| AIM Sector Fd.s -INVESCO VALUE OPPORTUNITIES Fd. | 2.06% |
| JPMorgan | 1.91% |
| Bank of Montreal /CAN/ | 1.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.84% |
| BlackRock | 10.5% |
| State Street | 2.64% |
Source: Nexqual, June 10, 2026 at 01:56 UTC.
From Globus Medical Inc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- We, and our third-party manufacturers, are subject to the quality system regulations of the FDA, state regulations (such as the regulations promulgated by the California Department of Health Services), and regulations promulgated by foreign regulatory bodies (such as in the European Union (the "EU")).
- Food and Drug Administration Regulation Our products meet the FDA's definition of medical devices (per Section 201(h)(1) of the Food, Drug, and Cosmetic Act) and human tissue products (under 21 CFR Parts 1270 and 1271 or Public Health Service Act Section 361), each subject to varying regulation(s) by the FDA and other federal, state, local and foreign regulatory bodies.
- Certain HCT/Ps are regulated solely under Section 361 of the Public Health Service Act and are referred to as "Section 361 HCT/Ps," while other HCT/Ps are subject to the FDA's regulatory requirements for medical devices or biologics in addition to the regulatory requirements under 21 CFR Parts 1270 and 1271.
- Our surgeon education and training program integrates surgical training with professional development and enables us to introduce surgeons to our comprehensive portfolio and patented approaches to spine surgery.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MASI | Masimo Corporation | USD 179.95 | ▲ 0.63% |
| WEX | WEX Inc. | USD 148.32 | ▲ 0.07% |
| APPN | Appian Corporation | USD 24.05 | ▼ 2.75% |
| IDXX | IDEXX Laboratories, Inc. | USD 578.89 | ▲ 2.98% |
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:56 UTC. This page is informational and not investment advice.